Create Free Account

By creating account you will get access to hot stocks & personalised emails

Resonance Health Ltd

Healthcare AU RHT

0.052AUD
-0.007(11.86%)

Last update at 2024-12-19T04:38:00Z

Day Range

0.050.06
LowHigh

52 Week Range

0.040.09
LowHigh

Fundamentals

  • Previous Close 0.06
  • Market Cap29.42M
  • Volume592459
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.45701M
  • Revenue TTM8.59M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 4.47M
  • Diluted EPS TTM-

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -1.26406M -1.55152M 0.34M -0.95270M 0.94M
Minority interest - - - - -
Net income -0.78036M -1.14178M 0.59M -0.71508M 1.27M
Selling general administrative 3.14M 2.50M 2.00M 3.57M 1.67M
Selling and marketing expenses 0.82M 1.02M 0.24M 0.24M 0.27M
Gross profit 4.40M 3.83M 3.78M 3.67M 3.62M
Reconciled depreciation 0.44M 0.43M 0.36M 0.34M 0.25M
Ebit -1.59339M -1.77245M 0.19M -1.17992M 0.87M
Ebitda -1.15703M -1.34334M 0.55M -0.83934M 1.11M
Depreciation and amortization 0.44M 0.43M 0.36M 0.34M 0.25M
Non operating income net other - - - - -
Operating income -1.59339M -1.77245M 0.19M -1.17992M 0.87M
Other operating expenses 6.03M 5.60M 3.59M 4.85M 2.76M
Interest expense - 0.00332M 0.16M 0.23M 0.07M
Tax provision -0.48370M -0.40975M -0.24233M -0.23762M -0.32856M
Interest income 0.29M 0.00332M 0.09M 0.00402M 0.04M
Net interest income 0.04M 0.00332M 0.04M 0.04M 0.04M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.48369M -0.40975M -0.24233M -0.23762M -0.32855M
Total revenue 4.40M 3.83M 3.78M 3.67M 3.62M
Total operating expenses 6.03M 5.60M 3.59M 4.85M 2.76M
Cost of revenue - - - - -
Total other income expense net 0.32M 0.22M 0.16M 0.23M 0.07M
Discontinued operations - - - - -
Net income from continuing ops -0.78036M -1.14178M 0.59M -0.71508M 1.27M
Net income applicable to common shares -0.78036M -1.14178M 0.59M -0.71508M 1.27M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 20.28M 10.98M 11.69M 12.44M 10.50M
Intangible assets - 2.71M 2.87M 2.59M 2.53M
Earning assets - - - - -
Other current assets 0.11M - 0.06M 0.04M 0.04M
Total liab 9.35M 1.05M 1.00M 0.61M 0.59M
Total stockholder equity 10.93M 9.94M 10.69M 11.83M 9.91M
Deferred long term liab - 2.71M 2.87M 2.59M 2.53M
Other current liab 5.34M 0.01M 0.46M 0.40M 0.41M
Common stock 74.17M 73.88M 73.88M 73.88M 72.57M
Capital stock - 73.88M 73.88M 73.88M 72.57M
Retained earnings -65.87240M -66.04170M -65.26134M -64.11956M -64.70542M
Other liab - - - - -
Good will 7.26M - - - -
Other assets - 2.80M 2.95M 2.64M 2.58M
Cash 3.40M 6.36M 6.78M 8.86M 6.97M
Cash and equivalents - 1.04M 6.78M 6.09M 6.97M
Total current liabilities 6.15M 0.88M 0.81M 0.61M 0.53M
Current deferred revenue 0.01M 0.62M 0.02M 0.03M 0.01M
Net debt 0.29M -6.08868M -6.51495M -8.79672M -6.85813M
Short term debt 0.49M 0.10M 0.08M 0.06M 0.06M
Short long term debt - - - - -
Short long term debt total 3.70M 0.27M 0.27M 0.06M 0.12M
Other stockholder equity - -0.27058M 2.07M 2.06M 2.05M
Property plant equipment - 0.63M 0.39M 0.11M 0.14M
Total current assets 9.29M 7.56M 8.35M 9.69M 7.78M
Long term investments - 0.08M 0.08M 0.05M 0.05M
Net tangible assets - 9.94M 10.69M 11.83M 9.91M
Short term investments 3.45M - - - -
Net receivables 2.32M 1.14M 1.51M 0.79M 0.77M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.30M 0.15M 0.24M 0.12M 0.05M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.64M 2.09M 2.07M 2.06M 2.05M
Additional paid in capital - - - - -
Common stock total equity - - - - 72.57M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.73M 0.08M 0.08M 0.05M 0.05M
Deferred long term asset charges - - - - -
Non current assets total 11.00M 3.43M 3.34M 2.75M 2.72M
Capital lease obligations - 0.27M 0.27M 0.06M 0.12M
Long term debt total - 0.17M 0.19M 0.00000M 0.06M
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Investments -3.94164M -0.46790M -0.70400M -0.39579M -0.25063M
Change to liabilities - 0.04M 0.20M 0.11M -0.04408M
Total cashflows from investing activities - -0.46790M -0.70400M -0.39579M -0.25063M
Net borrowings - -0.08197M -0.07013M -0.05189M -0.05167M
Total cash from financing activities 3.01M -0.08197M -0.10712M 1.20M 2.82M
Change to operating activities - 0.02M -0.04559M -0.03368M -0.00359M
Net income 0.17M -0.78036M -1.14178M 0.59M -0.71508M
Change in cash 0.49M -0.42154M -2.07365M 1.88M 3.89M
Begin period cash flow 6.36M 6.78M 8.86M 6.97M 3.08M
End period cash flow 6.85M 6.36M 6.78M 8.86M 6.97M
Total cash from operating activities 1.39M -0.15703M -0.71267M 1.17M 1.31M
Issuance of capital stock - - - 1.25M 2.89M
Depreciation 0.50M 0.44M 0.43M 0.36M 0.34M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.45044M 0.36M -0.71466M -0.02477M -0.10328M
Sale purchase of stock - - 0.00000M 1.25M -0.01500M
Other cashflows from financing activities -0.16414M -0.08197M -0.10712M -0.05189M -0.05167M
Change to netincome - -0.22947M -0.18699M 0.17M 1.84M
Capital expenditures 0.38M 0.47M 0.70M 0.40M 0.25M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.08831M 0.42M -0.55549M 0.05M -0.15094M
Stock based compensation 0.83M 0.02M 0.00562M 0.03M 1.85M
Other non cash items -0.01871M -0.22947M 0.56M 0.17M 1.84M
Free cash flow 1.01M -0.62493M -1.41667M 0.77M 1.06M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RHT
Resonance Health Ltd		 -0.007 11.86% 0.05 - - 3.42 2.86 3.27 -11.4219
PME
Pro Medicus Ltd		 -12.79 4.86% 250.23 318.92 232.56 163.02 137.59 159.06 212.75
ONE
Oneview Healthcare PLC		 -0.005 1.64% 0.30 - - 25.24 29.93 15.53 -3.5247
CGS
CogState Ltd		 -0.105 8.90% 1.07 24.00 26.45 4.77 3.22 2.36 10.34
MDR
Medadvisor Ltd		 -0.015 5.26% 0.27 - 25.97 1.35 3.21 1.33 23.05

Reports Covered

Stock Research & News

View All

Profile

Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices in Australia, the Asia Pacific, North America, Europe, the Middle East, and Africa. The company offers FerriScan, a non-invasive MRI based solution for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) solution for the automated real-time assessment of LIC; HepaFatScan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; HepaFatSmart, an AI-trained device for the automated real-time multi-metric measurement of liver-fat; LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFatSmart into a consolidated report; and CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading. It also provides phantoms for MRI machines. In addition, the company operates as an imaging contract research organization that provides proposal and project management support, site set-up, imaging charter development, clinical reports, data transfer agreements, and compliance services for clinical trial sponsors. It serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for their clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.

Resonance Health Ltd

141-143 Burswood Road, Burswood, WA, Australia, 6100

Key Executives

Name Title Year Born
Mr. Mitchell M. Wells B.Com., B.Comm, L.L.B., LLB MD, Joint Company Sec. & Exec. Director 1975
Mr. Nicholas Allan A.C.A., B.Com. CFO, COO & Joint Company Sec. NA
Mr. Ben Winters Chief Technology Officer NA
Ms. Liesl Ellies Gen. Counsel & Joint Company Sec. NA
Mr. Chad Tondut Communications Mang. and GM of Products & Portfolio NA
Mr. Ajay Nair Gen. Mang. of Global Sales & Marketing NA
Dr. John Olynyk BMedSc, FRACP, M.D., MBBS Chief Medical Officer NA
Dr. Timothy Guy St. Pierre B.Sc(Hons), Ph.D. Chief Research Scientist NA
Dr. Wenjie Pang Ph.D. Chief Scientific Officer ? Imaging & AI NA
Dr. Sherif Boulos Ph.D. Chief Scientific Officer of Molecular NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.